Industry Liaison Forum

The ILF highlights the perspective of the HIV biomedical industry and catalyses multi-stakeholder dialogue, engagement and actions to address barriers along the HIV cascade and cross-cutting issues.

The work of the ILF is guided by a strong, multi-stakeholder advisory group, which is composed of industry and non-industry representatives.

The ILF focuses on three areas:

  • Collaboration platform
  • Paediatric HIV
  • Regulatory affairs.

Learn more here.


Latest Publications


CTA/ILF/CIPHER Thematic Roundtable on Paediatric ARVs: Fast tracking development of priority formulations

The ILF and CIPHER, with the Global Pediatric Antiretroviral Commitment-to-Action (CTA) partner organizations, recently convened a workshop to discuss a new framework of collaboration for accelerating the development of the most-needed paediatric antiretroviral (ARV) drugs.

The workshop built on previous discussions around developing a global accelerator for paediatric formulations, a collaborative framework potentially supported by an innovative financing mechanism, to fast track development of paediatric ARVs. This type of collaborative framework could also serve as a model for tuberculosis and other disease areas.

In the context of existing broader constraints to paediatric ARV development, stakeholders also agreed on the need for a range of actions, including:

  • Reviewing the current age-staggered approach for development of new products in order to include adolescents in initial (registrational) adult efficacy trials and promote simultaneous enrolment of children in different age groups
  • Developing age-appropriate paediatric formulations earlier in the process of testing new drugs in adults in order to minimize the paediatric formulation development and approval timelines
  • More systematic coordination between regulators, industry and research networks during the development and review of paediatric implementation plans (PIPs) and pediatric study plans (PSPs)
  • Simplifying the PIP/PSP modification processes
  • Encouraging other regulators to recognize and act on Paediatric ARV Drug Optimization (PADO) priorities to speed up in-country introduction
  • Improving the collaboration and alignment between regulatory authorities
  • Increasing information sharing, especially for PADO deliberations, to industry and regulators
  • Exploring alternative options to leverage generic industry engagement and potentially provide assistance to PIPs/PSPs
  • Developing incentives to stimulate paediatric formulation development by targeting the steps of biggest concern (i.e., financing clinical trials, in-country registration, demand creation and consolidation).

Stakeholders agreed that the proposed framework could be a useful mechanism for supporting faster paediatric ARV development. Industry representatives noted that while lack of funds to develop paediatric ARVs may not be the only limitation as long as drugs are purchased once developed, financial support may be required for other steps in the cascade from research to development to introduction. To that end, further discussion is needed to fully articulate what the funding would support.

Download the meeting report



ILF Thematic Roundtable on HIV Diagnostics

The improvement of early infant diagnosis (EID) through the implementation of point-of-care (POC) diagnostics has been identified as an important contribution to achieving the first of the three 90s of the UNAIDS 90-90-90 goals (HIV diagnosis) among HIV-exposed infants, and therefore also to achieving the other 90s goals. This meeting provided an opportunity to review the progress made in optimizing EID testing and securing and improving patients’ and caregivers’ access to quality EID and POC diagnostics. These elements are essential to improving subsequent paediatric care and treatment for HIV-infected infants in low- and middle-income countries.

The two key take-home messages from this interactive discussion are:

  • Scaling up POC EID now – There is an urgent need for rapid implementation of the available POC EID platforms. Planned, individual country evaluations are unnecessary, and current efforts should focus on rapid implementation programmes. Impact evaluations should similarly inform the best use and placement of POC EID systems.
     
  • Investing in QA – All actors – funders, ministries of health, health care professionals and implementers – should consider QA for POC as an investment, not a cost. QA should become an integral part of all POC diagnostics programmes.

Download the meeting report




How to meet the first-ever global hepatitis targets

Blog post by Sébastien Morin, Eliot Ross Albers and Jürgen Rockstroh

HCV has historically been under-estimated, under-prioritized and under-resourced in comparison to the significant impact it has on millions of people around the world. However, with the adoption of the global hepatitis targets this is changing and an HCV-free generation, where the disease is no longer a great public health concern, is on the horizon.

Read the full post



ILF/CIPHER Thematic Roundtable on Paediatric ARVs: Stimulating Development of the most needed formulations

The global community has identified priorities for future research and development for paediatric ARV formulations through the Paediatric ARV Drug Optimization (PADO) meetings; however, there are many challenges to making these formulations available. Although coordinated procurement efforts have been successful in reducing market fragmentation, the paediatric market is small compared with adults, and manufacturers do not have incentives to develop these priority paediatric formulations. Existing regulatory frameworks promote development of paediatric formulations, but implementation of those frameworks may have resulted in inefficient allocation of resources for paediatric research and development. In addition, the success in preventing mother-to-child transmission has reduced the number of new HIV infections, making it increasingly challenging to conduct robust clinical trial to assess efficacy, safety and acceptability of new paediatric drugs and fixed dose combinations across the age spectrum.

The ILF and CIPHER jointly held this technical meeting, which delivered information on the gaps between available and most needed paediatric ARV formulations and some existing innovative funding mechanisms and partnerships to support collaborative research and development between the public and private sectors. Creative solutions to alternative financing mechanisms, which build upon existing regulatory processes, to optimize the investment in paediatric ARVs, and enable a more sustainable development of prioritized products were discussed to ensure availability of the best treatment for infants and children living with HIV in the future.

Download the meeting report



Modern HIV prevention: what’s next for women?

Blog post by Lisa Levin, Cate Hankins, Brent Allan, Rahab Mwaniki, Nelli Bazarova, Sébastien Morin, and Linda-Gail Bekker

Today, some of the world’s leading scientists and researchers were gathered in Boston at the Conference on Retroviruses and Opportunistic Infections (CROI). “What’s next for women?” was the question on the minds of many, after results were released from two trials that looked at one of the most promising new HIV prevention tools of our time: the long-acting dapivirine vaginal ring, a female-controlled HIV prevention method that could potentially protect women for up to a month at a time.

Read the full post



ILF Annual Report 2015

In 2015, the ILF catalysed multi-stakeholder discussions in a diversity of fields aligned with IAS Member Priorities. In addition, the ILF Advisory Group continued to expand, and now includes a broader range of industry and non-industry participants from diverse sectors. These were the major ILF activities in 2015:

  • ILF Thematic Roundtable on Key Populations
  • ILF/CIPHER Thematic Roundtable on Paediatric ARVs: Aligning, Coordinating and Accelerating Actions to Provide Better ARVs for Children
  • ILF/CIPHER Thematic Roundtable on Paediatric HIV Diagnostics: Early Infant Diagnosis and Beyond
  • ILF/Co-Infections Thematic Roundtable on the Road to HCV Elimination
  • IAS-Industry Consultation on Integration of HIV and Other Diseases: From Single Disease to Complete Patient Management
  • ILF Advisory Group Meeting on Strategies for an Impactful ILF in 2016 and Beyond.

Download the annual report



ILF/CIPHER Thematic Roundtable on Paediatric HIV Diagnostics
From development to implementation, there are challenges in paediatric HIV diagnostics. The 2013 WHO guidelines recommended virological testing of infants at risk of perinatal and intra-partum HIV infection between four and six weeks of age. Moving forward, there are discussions around testing infants earlier and closer to the point of care to ensure that HIV-exposed infants are identified as early as possible, and can begin treatment as soon as possible because HIV-infected infants otherwise often die in the first months of life. This will also require expanding the testing net and integrating HIV testing in other health care platforms to identify children who are not picked up through the established prevention of mother-to-child transmission cascade. The ILF and CIPHER jointly held this technical meeting, which delivered information on the paediatric HIV diagnostics continuum, highlighting challenges and existing initiatives, alongside an overview of WHO guidance and guideline development. Creative solutions to overcome barriers of the development and the delivery of optimal paediatric HIV diagnostics were discussed.

Download the meeting report



ILF Corporate Partners



See the list of previous industry partners   |   Learn about the ILF Corporate Partnership Programme